United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

Key Points

• CEO insider sale: United Therapeutics CEO Martine Rothblatt sold 9,500 shares at an average price of $493.46, generating approximately $4.69 million. She retained 324,443 shares valued at about $160.1 million.
• Stock and earnings: UTHR shares recently traded near $490, below their 50-day and 200-day moving averages. The company beat quarterly EPS estimates with $7.27 per share, though revenue fell 1.9% year over year to $783.3 million.
• Analyst outlook remains positive: Eleven analysts rate the stock a Buy and two rate it a Hold, resulting in a “Moderate Buy” consensus rating and an average price target of $646. Institutional investors own approximately 94.08% of the company.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total value of $4,687,870.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $160,099,642.78. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $1.78 during midday trading on Thursday, reaching $490.24. The company's stock had a trading volume of 469,574 shares, compared to its average volume of 494,247. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35. The company has a market capitalization of $21.03 billion, a P/E ratio of 17.54, a P/E/G ratio of 2.56 and a beta of 0.56. The business's fifty day simple moving average is $528.12 and its 200-day simple moving average is $539.79.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company earned $6.41 EPS. The firm's quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock valued at $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $277,000. Cerity Partners LLC lifted its stake in shares of United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its stake in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on UTHR shares. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source